 RTT News | Fall in Avastin sales and strong franc hurt Roche financials Pharma Times The firm's top-selling drug in the quarter was MabThera/Rituxan (rituximab), for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthritis. It contributed 4.42 billion francs, an increase of 7%, although Avastin ... Flat sales at Roche as Swiss franc strength, health spending cuts and Avastin ... |
